

Quick Heal Technologies Ltd.

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune 411014. Tel: +91 20 66813232 | Email: cs@quickheal.co.in CIN - L72200MH1995PLC091408

Ref No.: QHTL/Sec/SE/2021-22/11

The Manager, Corporate Services, BSE Limited, 14th floor, P J Towers, Dalal Street, Mumbai – 400 001 Ref: Security ID : QUICKHEAL Security Code: 539678 May 15, 2021

The Manager, Corporate Services, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: QUICKHEAL Series : EQ

Subject: Outcome of Board Meeting May 15, 2021

Dear Sir / Madam,

We wish to inform you that the Board of Directors at its meeting held on May 15, 2021 through video conferencing which commenced at 02:50 PM and concluded at 6:30 PM, has approved following:

- 1. Audited Financial Results of the Company for the financial year ended March 31, 2021, both Standalone and consolidated.
- Pursuant to Regulation 33 of SEBI Regulations, we have enclosed herewith Audit Report for the audited financial results both standalone and consolidated for the financial year ended 31st March 2021 (including Form A for both standalone and consolidated) from our Statutory Auditors M/s MSKA & Associates, Chartered Accountants.
- 3. A Presentation in respect of aforesaid financial results
- 4. A copy of the Press Release being issued in respect of aforesaid financial results.
- 5. The Board has recommended a final dividend of ₹ 4 per equity share of ₹ 10 each for the year 2020-21

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the regulations"), a declaration that Statutory Auditors of the Company have issued an Audit Report with Unmodified opinion on the Audited Financial Results of the Company (Standalone and Consolidated) for the quarter and year ended March 31, 2021.

As permitted, this letter is being submitted under Sd/- mode due to work from home as per the Government advisory on Covid-19 and as a part of safety measure.

This is for your information and records.

For Quick Heal Technologies Limited

Sd/-

A. Srinivasa Rao Company Secretary

	Regd. Office: Marvel Edge, Office No. 7010 C & D, CIN: L	7th Floor, Opposite Neco 72200MH1995PLC09140		Nagar, Pune - 411014		
	STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK H	EAL TECHNOLOGIES I	LIMITED FOR THE QU	ARTER AND YEAR EN		
					,	ept earning per shar
ə			Quarter ended		Year ei	
Sr. No	Particulars	March 31, 2021 (Audited)	December 31, 2020 (Unaudited)	March 31, 2020 (Audited)	March 31, 2021 (Audited)	March 31, 2020 (Audited)
1	Income					
	Revenue from operations	1,052.94	698.75	642.54	3,330.44	2,861.3
	Other income	57.34	62.87	82.42	241.61	315.9
	Total income	1,110.28	761.62	724.96	3,572.05	3,177.3
2	Expenses					
	Cost of raw materials consumed	3.60	1.80	0.19	10.27	8.1
	Purchase of security software products	40.43	6.62	45.70	83.29	95.
	Changes in inventories of security software products	(4.07)	12.98	(17.00)	22.78	(3.
	Employee benefits expense	315.10	289.82	245.81	1,147.44	1,014.
	Depreciation and amortisation expense	50.00	49.57	55.93	194.87	216.7
	Other expenses	160.10	222.90	291.99	652.03	833.
	Total expenses	565.16	583.69	622.62	2,110.68	2,164.
3	Profit / (loss) before tax (1-2)	545.12	177.93	102.34	1,461.37	1,013.
4	Tax expense					
	Current tax					
	Pertaining to profit for the current period	111.01	23.25	2.83	340.38	211.
	Adjustments of tax relating to earlier periods	17.56	-	2.05	17.56	211.
	Deferred tax	19.29	20.07	19.58	33.63	57.
	Total tax expense	147.86	43.32	22.41	391.57	269.
5	Profit / (loss) for the period (3-4)	397.26	134.61	79.93	1,069.80	744.
6	Other comprehensive income, net of tax					
0	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:					
	Re-measurement of defined benefit plans	4.13	(4.17)	1.25	1.26	9.1
	Other comprehensive income to be reclassified to profit or loss in subsequent periods:	(0.72)	(0.37)	1.81	(3.60)	2.
	Exchange differences on translation of foreign operations	(0.72)	(0.37)	1.81	(3.00)	2.
	Total other comprehensive income	3.41	(4.54)	3.06	(2.34)	11.
7	Total comprehensive income (after tax) (5+6)	400.67	130.07	82.99	1,067.46	756.
8	Paid-up equity share capital (face value of ₹10 each)	642.07	642.05	642.03	642.07	642.
9	Other equity (as per balance sheet of previous accounting year)				6,872.79	5,798.
10	Earnings per share of ₹10 each:					
	(not annualised for the quarter)					
		< 10	0.10	1.04	17.77	
	a) Basic	6.19	2.10	1.24	16.66	11.
	b) Diluted	6.19	2.09	1.24	16.65	11

		Audited standalone financial inform	ation					
SF: Norch 21, 2021 Norch 21, 2020 Morch 21, 2020 Morch 21, 2021 Morch 21, 2021								
a			Quarter ended					
sr. No	Particulars	March 31, 2021 (Audited)	December 31, 2020 (Unaudited)	March 31, 2020 (Audited)	March 31, 2021 (Audited)	March 31, 2020 (Audited)		
	Revenue from operations	1,061.05	711.23	634.31	3,335.28	2,834.0		
	Profit before tax	548.00	170.21	82.33	1,458.37	1,004.4		
3	Profit after tax	400.38	127.22	60.24	1,067.94	736.3		
	s to financial results:							
1	The above financial results for the year ended March 31, 2021 have been subjected to Statutory Audit by the Statutory Auditors of the Group and reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at the meeting held on May 15, 2021. Figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine month ended December 31, 2020 and December 31, 2019 respectively.							
2	During the year ended March 31, 2019, The Parent Company had received notice of penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-		-			-		
	During the earlier years, The Parent Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹1,223.07 million (excluding penalty of ₹626.97 million and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. The Parent Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April 1, 2014 to March 31, 2016.							
The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 the Service Tax demand for ₹560.71 million along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 control the period March 1, 2011 to March 31, 2014.					••	· · ·		
	Based on this latest judgement of CESTAT, New Delhi, technical circular issued by and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, I				ier years, the Company is	confident to get reli		
	The Commissioner of Service Tax, Delhi has preferred an appeal against the above s admission level is pending with the Hon'ble Supreme Court.	aid Order passed by the Hon'ble Customs, E	xcise & Service Tax Appe	llate Tribunal (CESTAT)	amounting to ₹560.71 mil	lion and hearing for		
3	The Board of Directors of the Parent Company at its meeting held on March 10, 202 value of ₹10 each from its shareholder/beneficial owners of equity shares of the Pare offer" route at a price of ₹245 per share for an aggregate amount not exceeding ₹1,5: Further, the Parent Company has received final SEBI observations on the DLoF and May 21, 2021.	ent Company including promoters of the Pare 50. The parent Company had filed the draft l	ent Company as on the reco etter of offer (DLoF) with	ord date i.e. May 03, 2021 Securities and Exchange I	on a proportionate basis t Board of India (SEBI) on	hrough the "tender April 27, 2021.		
4	The Board of Directors have recommended the dividend of ₹4 per equity share of the ensuing Annual General Meeting of the Company.	e face value of ₹10.00 per share for the year	ended March 31, 2021. Th	e payment of dividend is s	subject to approval of the	shareholders at the		
5	The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".							
6 Estimated uncertainty relating to COVID-19 outbreak The Management has made an assessment of the impact of COVID-19 on the Group's operations, financial performance and position as at and for the quarter and year ended March 31, 2021 and has concluded th primarily on the operational aspects of the business. In assessing the recoverability of receivables, investments, and other assets, the Group has considered internal and external information up to the date of appre financial results including status of existing and future customer orders, cash flow forecasts, commitments with suppliers, etc. The Group has performed sensitivity analysis on the assumptions used and based on of future economic conditions, the Group expects to recover the carrying amount of these assets, the Group has also considered the impact of subsequent events in its assessment and concluded that there is no si which is required to be recognised in the financial results. Accordingly, no further adjustments have been made to the financial results.						oproval of these on current indicators		

	The Code on Social Security 2020 ('the Code') relating to employee benefits, during employment and post-employment, has rec Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effor financial impact are also not yet issued.		
	The Parent Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period	d in which, the Code becomes effective	
8	Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period	d's classification / disclosure.	
		For	and on behalf of the Board of Directors
		Kailash Digitally signed by Kailash Sahebrao Katkar DN:	

QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

			Quarter ended			cept earning per share ended
Sr. No	Particulars	March 31, 2021 (Audited)	December 31, 2020 (Unaudited)	March 31, 2020 (Audited)	March 31, 2021 (Audited)	March 31, 2020 (Audited)
1	Income					
	Revenue from operations	1,052.94	698.75	642.54	3,330.44	2,861.38
	Other income	57.34	62.87	82.42	241.61	315.96
	Total income	1,110.28	761.62	724.96	3,572.05	3,177.34
2	Expenses					
	Cost of raw materials consumed	3.60	1.80	0.19	10.27	8.16
	Purchase of security software products	40.43	6.62	45.70	83.29	95.94
	Changes in inventories of security software products	(4.07)	12.98	(17.00)	22.78	(3.86
	Employee benefits expense	315.10	289.82	245.81	1,147.44	1,014.19
	Depreciation and amortisation expense	50.00	49.57	55.93	194.87	216.77
	Other expenses	160.10	222.90	291.99	652.03	833.03
	Total expenses	565.16	583.69	622.62	2,110.68	2,164.23
3	Profit / (loss) before tax (1-2)	545.12	177.93	102.34	1,461.37	1,013.11
4	Tax expense					
•	Current tax					
	Pertaining to profit for the current period	111.01	23.25	2.83	340.38	211.44
	Adjustments of tax relating to earlier periods	17.56	23.25	2.05	17.56	-
	Deferred tax	19.29	20.07	19.58	33.63	57.56
	Total tax expense	147.86	43.32	22.41	391.57	269.00
5	Profit / (loss) for the period (3-4)	397.26	134.61	79.93	1,069.80	744.11
6	Other comprehensive income, net of tax					
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:					
	Re-measurement of defined benefit plans	4.13	(4.17)	1.25	1.26	9.73
	Other comprehensive income to be reclassified to profit or loss in subsequent periods:					
	Exchange differences on translation of foreign operations	(0.72)	(0.37)	1.81	(3.60)	2.16
	Total other comprehensive income	3.41	(4.54)	3.06	(2.34)	11.89
7	Total comprehensive income (after tax) (5+6)	400.67	130.07	82.99	1,067.46	756.00
8	Paid-up equity share capital (face value of ₹10 each)	642.07	642.05	642.03	642.07	642.03
9	Other equity (as per balance sheet of previous accounting year)				6,872.79	5,798.65
10	Earnings per share of ₹10 each:					
10	(not annualised for the quarter)					
	a) Basic	6.19	2.10	1.24	16.66	11.34
	b) Diluted	6.19	2.09	1.24	16.65	11.34

	QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408
	NOTES TO THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE YEAR ENDED MARCH 31, 2021
Not	es to financial results:
1	The above financial results for the year ended March 31, 2021 have been subjected to Statutory Audit by the Statutory Auditors of the Group and reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at the meeting held on May 15, 2021. Figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine month ended December 31, 2020 and December 31, 2019 respectively.
2	During the year ended March 31, 2019, The Parent Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹ 387.43 million (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.
	During the earlier years, The Parent Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹ 1,223.07 million (excluding penalty of ₹ 626.97 million and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. The Parent Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, Mumbai for the period April 1, 2014 to March 31, 2016.
	The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax demand for ₹ 560.71 million along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 covering period from for the period March 1, 2011 to March 31, 2014.
	Based on this latest judgement of CESTAT, New Delhi, technical circular issued by government authorities and an independent legal opinion obtained by the Parent Company in earlier years, the Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability had been recognized/disclosed in the financial statements.
	The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹ 560.71 million and hearing for admission level is pending with the Hon'ble Supreme Court.
3	The Board of Directors of the parent Company at its meeting held on March 10, 2021 and the shareholders by way of postal ballot on April 18, 2021 approved the buy back of the Company's fully paid equity shares of the face value of ₹ 10 each from its shareholder/beneficial owners of equity shares of the parent Company including promoters of the parent Company as on the record date i.e. May 03, 2021 on a proportionate basis through the "tender offer" route at a price of ₹ 245 per share for an aggregate amount not exceeding ₹ 1,550. The parent Company had filed the draft letter of offer (DLoF) with Securities and Exchange Board of India (SEBI) on April 27, 2021. Further, the parent Company has received final SEBI observations on the DLoF and shall be dispatching the Letter of Offer for the Buyback to the eligible shareholders appearing on the record date of May 03, 2021, on or before May 21, 2021.
4	The Board of Directors have recommended the dividend of $\gtrless 4$ per equity share of the face value of $\gtrless 10.00$ per share for the year ended March 31, 2021. The payment of dividend is subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
5	The Group is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
6	Estimated uncertainty relating to COVID-19 outbreak The Management has made an assessment of the impact of COVID-19 on the Group's operations, financial performance and position as at and for the quarter and year ended March 31, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In assessing the recoverability of receivables, investments, and other assets, the Group has considered internal and external information up to the date of approval of these financial results including status of existing and future customer orders, cash flow forecasts, commitments with suppliers, etc. The Group has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Group expects to recover the carrying amount of these assets, the Group has also considered the impact of subsequent events in its assessment and concluded that there is no significant impact which is required to be recognised in the financial results. Accordingly, no further adjustments have been made to the financial results.
	Considering the dynamic nature of the issue, the impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Group will continue to closely monitor any material changes to future economic conditions
7	The Code on Social Security 2020 ('the Code') relating to employee benefits, during employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued.
	The Parent Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective
8	Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.
	For and on behalf of the Board of Directors
	Kailash Republication Kaitar
	Sahebrao
	e: Pune Katkar

QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

	As at March 31, 2021 (Audited)	earning per share) As at March 31, 2020 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	1,404.67	1,485.09
(b) Capital work-in-progress	21.10	34.00
(c) Intangible assets	52.81	99.81
(d) Financial assets		
(i) Investments	322.00	353.32
(ii) Loans and security deposits	3.75	3.81
(iii) Other financial assets	1.62	3.91
(e) Deferred tax assets (net)	-	25.86
(f) Income tax assets (net)	121.49	167.92
(g) Other non-current assets	24.64	5.32
	1,952.08	2,179.04
Current assets		,
(a) Inventories	33.35	62.40
(b) Financial assets		
(i) Investments	3,833.10	2.745.22
(i) Trade receivables	1,506.30	1,131.62
(iii) Cash and cash equivalents	1,500.50	1,151.02
	678.87	699.53
(iv) Bank balances other than (iii) above		7.74
(v) Loans and security deposits	6.79	
(vi) Interest accrued	7.95	15.26
(c) Other current assets	68.18	24.13
(d) Assets classified as held for sale	16.02	-
Total assets	6,314.79 8,266.87	4,786.62
Equity and liabilities		•,• ••••
Equity		
(a) Equity share capital	642.07	642.03
(b) Share application money pending allotment	-	-
(c) Other equity		
(i) Retained earnings	5,778.87	4,707.81
(ii) Securities premium	594.33	593.84
(iii) Amalgamation reserve	26.45	26.45
(iv) General reserve	450.26	450.26
(v) Capital redemption reserve	63.64	63.64
(vi) Other reserves	(40.76)	(43.35)
Total equity	7,514.86	6,440.68
Liabilities		,
Non-current liabilities		
(a) Net employee defined benefit liabilities	3.72	4.62
(b) Other non-current liabilities	5.12	19.63
(c) Deferred tax liability (net)	8.19	-
(c) Detered tax hability (let)	11.91	24.25
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	13.28	4.73
(b) Total outstanding dues creditors other than micro enterprises and enterprises	486.49	382.54
(ii) Other financial liabilities	13.30	9.04
(b) Other current liabilities	183.07	86.68
(c) Net employee defined benefit liabilities	11.66	3.94
(d) Income tax liabilities (net)	32.30	13.80
	740.10	500.73
Total liabilities	752.01	524.98
Total equity and liabilities	8,266.87	6,965.66

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT MARCH 31, 2021

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

CONSOLIDATED STATEMENT OF CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2021

		pt earning per share
		ended
	March 31, 2021 (Audited)	March 31, 2020 (Audited)
A. Cash flow from operating activities		
Profit before tax	1,461.37	1,013.11
Adjustment to reconcile profit before tax to net cash flows:		
Net (gain) / loss foreign exchange differences	(3.60)	0.95
Employee share based payments expense	6.21	1.70
Depreciation and amortization expense	194.87	216.77
Interest income	(71.27)	(81.29
Provision for doubtful debts and advances	(38.10)	62.83
Bad debts / property, plant and equipment written off	34.82	2.37
(Profit) / Loss on sale of property, plant and equipment	(0.37)	(5.30
Dividend income	-	(67.92
Exchange difference on translation of foreign currency cash and cash equivalents	0.70	(2.80
Net (gain) on sale of investment	(30.12)	(28.36
Net (gain) / loss on FVTPL current investment	(90.03)	(66.28
Operating profit before working capital changes	1,464.48	1,045.78
Movements in working capital:		
(Increase)/decrease in trade receivables	(371.40)	54.91
(Increase)/decrease in inventories	29.05	(8.46
(Increase)/decrease in loans	1.01	(0.74
	2.29	0.13
(Increase)/decrease in other financial assets		
(Increase)/decrease in other assets	(21.61)	15.32
Increase/(decrease) in net employee defined benefit liabilities	8.50	(18.03
Increase/(decrease) in trade payables	92.46	(0.49
Increase/(decrease) in other current liabilities	76.76	(49.09
Cash generated from operations	1,281.54	1,039.33
Direct taxes paid (net of refunds)	(293.01)	(333.72
Net cash flow from operating activities (A)	988.53	705.61
B. Cash flow from investing activities		
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and	(88.58)	(113.22
capital advances)	(88.58)	(115.22
Proceeds from sale of property, plant and equipment	0.44	10.98
Investments in non-current investments (other)	31.32	(57.09
Purchase of current investments	(6,218.89)	(6,621.26
Sale of current investments	5,251.16	7,572.85
(Increase)/decrease in bank balances other than cash and cash equivalents	20.66	519.91
Interest received	78.58	96.71
Dividends received	-	67.92
Net cash (used in) investing activities (B)	(925.31)	1,476.80
C. Cash flow from financing activities		
Dividend paid on equity shares	0.49	(384.68
Tax on equity dividend paid	_	(79.65
Proceeds from issuance of equity shares (including securities premium and Buy back)	0.50	0.25
	0.50	
Payout on Buyback of equity shares	0.99	(1,750.00
Net cash flow (used in) financing activities (C)		(2,214.08
Net (decrease) in cash and cash equivalents (A+B+C)	64.21	(31.64
Cash and cash equivalents at the beginning of the year	100.72	129.56
Effect of exchange differences on cash and cash equivalents held in foreign currency	(0.70)	2.80
Cash and cash equivalents at the end of the year	164.23	100.72
Components of cash and cash equivalents		
Cash on hand	0.55	0.63
Balances with banks		
On current account	131.61	77.45
On EEFC account	31.36	3.09
		5.07
Cheques on hand	0.71	19.55

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

						n, except per share data)
Sr. No	Particulars	March 31, 2021 (Audited)	Quarter ended December 31, 2020 (Unaudited)	March 31, 2020 (Audited)	Year e March 31, 2021 (Audited)	nded March 31, 2020 (Audited)
1	Income	(Huuntu)	(Chuddhed)	(nunteu)	(Puuncu)	(Huuncu)
	Revenue from operations	1,061.05	711.23	634.31	3,335.28	2,834.04
	Other income	57.24	62.31	81.12	239.37	313.41
	Total income	1,118.29	773.54	715.43	3,574.65	3,147.45
2	Expenses					
	Cost of raw materials consumed	3.60	1.80	0.19	10.27	8.16
	Purchase of security software products	40.40	6.43	45.70	80.45	95.94
	Increase / (decrease) in inventories of security software products	(3.90)	12.98	(21.34)	22.96	(16.18)
	Employee benefits expense	311.35	285.97	242.04	1,131.97	999.90
	Depreciation and amortisation expense	49.98	49.56	55.88	194.78	216.64
	Other expenses Total expenses	168.86 570.29	246.59 603.33	287.46 609.93	675.85 2,116.28	815.42 2,119.88
3	Profit / (Loss) before exceptional items and tax (1-2)	548.00	170.21	105.50	1,458.37	1,027.57
4	Exceptional items (refer note 3)	-	-	23.17	-	23.17
5	Profit / (Loss) before tax (3-4)	548.00	170.21	82.33	1,458.37	1,004.40
	Tax expense				_,	_,
0	Current tax					
	Pertaining to profit for the current period	110.77	22.92	2.51	339.24	210.45
	Adjustments of tax relating to earlier periods (Net)	17.56		-	17.56	-
	Deferred tax	19.29	20.07	19.58	33.63	57.56
	Total tax expense	147.62	42.99	22.09	390.43	268.01
7	Profit / (Loss)for the period (5-6)	400.38	127.22	60.24	1,067.94	736.39
8	Other comprehensive income, net of tax					
	Other comprehensive income not to be reclassified to profit or loss in subsequent periods:					
	Re-measurement of defined benefit plans	4.13	(4.17)	1.25	1.26	9.73
	Other comprehensive income to be reclassified to profit or loss in subsequent periods	-	-	-	-	-
	Total other comprehensive income	4.13	(4.17)	1.25	1.26	9.73
9	Total comprehensive income (after tax) (7+8)	404.51	123.05	61.49	1,069.20	746.12
10	Paid-up equity share capital (face value of ₹ 10 each)	642.07	642.05	642.03	642.07	642.03
11	Other equity (as per balance sheet of previous accounting year)	-	-	-	6,915.97	5,840.10
12	Earnings per share of ₹ 10 each:					
	(not annualised except for the year ended March)					
	a) Basic	6.24	1.98	0.94	16.64	11.23
	b) Diluted	6.22	1.98	0.94	16.62	11.22

QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

Notes to financial results:

1 The above financial results for the year ended March 31, 2021 have been subjected to statutory audit by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on May 15, 2021. Figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between the audited figures in respect of the full years and published year to date figures of nine month ended December 31, 2020 and December 31, 2019 respectively.

2 During the year ended March 31, 2019, Company had received notice of demand dated March 13, 2019, in relation to service tax under the provisions of Finance Act, 1994 for ₹ 387.43 (excluding interest and penalties) covering the period from April 1, 2016 to June 30, 2017 on supply of anti-virus software in Compact Disk. Company replied to the notice of demand to Commissioner of Goods and Service Tax, Pune.

During the earlier years, Company received similar notice of demands in relation to service tax under the provisions of Finance Act, 1994 for ₹ 1,223.07 (excluding penalty of ₹ 626.97 and pre-deposit, if any) covering the period from March 1, 2011 to March 31, 2016 on supply of anti-virus software in Compact Disk. Company had filed an appeal with Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period March 1, 2011 to March 31, 2014 and with the Customs, Excise and Service Tax Appellate Tribunal, New Delhi for the period April 1, 2014 to March 31, 2016.

The Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Principal Bench, New Delhi, vide its judgment (Order No. 50022/2020) dated January 09, 2020 (Service Tax Appeal No. 51175 of 2016), has set aside the Service Tax demand for ₹ 560.71 along with interest and penalty which was earlier confirmed by Directorate General of Central Excise Intelligence (DGCEI), New Delhi vide its Order of 2016 covering period from for the period March 1, 2011 to March 31, 2014.

Based on this latest judgement of CESTAT, New Delhi, technical circular issued by government authorities and an independent legal opinion obtained by the Company in earlier years, the Company is confident to get relief and set aside for balance period from April 01, 2014 to June 30, 2017. Accordingly, no provision/contingent liability had been recognized/disclosed in the financial statements.

The Commissioner of Service Tax, Delhi has preferred an appeal against the above said Order passed by the Hon'ble Customs, Excise & Service Tax Appellate Tribunal (CESTAT) amounting to ₹ 560.71 and hearing for admission level is pending with the Hon'ble Supreme Court.

3 Impairment of investments

Included in exceptional items						
Particulars		Standalone				
	Quarter ended Year ended				ended	
	March 31, 2021	December 31, 2020	March 31, 2020	March 31, 2021	March 31, 2020	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
Impairment of investment in wholly owned subsidiaries	-	-	23.17	-	23.17	

- 4 The Board of Directors of the Company at its meeting held on March 10, 2021 and the shareholders by way of postal ballot on April 18, 2021 approved the buy back of the Company's fully paid equity shares of the face value of ₹10 each from its shareholder/beneficial owners of equity shares of the Company including promoters of the Company as on the record date i.e. May 03, 2021 on a proportionate basis through the "tender offer" route at a price of ₹245 per share for an aggregate amount not exceeding ₹1,550. The Company had filed the draft letter of offer (DLoF) with Securities and Exchange Board of India (SEBI) on April 27, 2021. Further, the Company has received final SEBI observations on the DLoF and shall be dispatching the Letter of Offer for the Buyback to the eligible shareholders appearing on the record date of May 03, 2021, on or before May 21, 2021.
- 5 The Board of Directors have recommended the dividend of ₹4 per equity share of the face value of ₹10.00 per share for the year ended March 31, 2021. The payment of dividend is subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
- 6 The Company is engaged in providing security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. retail, enterprise & government and mobile. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. anti-virus and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 7 The Code on Social Security 2020 ('the Code') relating to employee benefits, during employment and post-employment, has received Presidential assent on September 28, 2020. The Code has been published in the Gazette of India. Further, the Ministry of Labour and Employment has released draft rules for the Code on November 13, 2020. However, the effective date from which the changes are applicable is yet to be notified and rules for quantifying the financial impact are also not yet issued.

The Company will assess the impact of the Code and will give appropriate impact in the financial statements in the period in which, the Code becomes effective.

QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF STANDALONE FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

Notes to financial results:

8 Estimated uncertainty relating to COVID-I9 outbreak

The management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the quarter and year ended March 31, 2021 and has concluded that the impact is primarily on the operational aspects of the business. In assessing the recoverability of receivables, investments, and other assets, the Company has considered internal and external information up to the date of approval of these financial results including status of existing and future customer orders, cash flow forecasts, commitments with suppliers, etc. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets, the Company has los considered the impact of subsequent events in its assessment and concluded that there is no significant impact which is required to be recognised in the financial results. Accordingly, no further adjustments have been made to the financial results.

Considering the dynamic nature of the issue, the impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.

9 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

	Kailash	Digitally signed by Kailash Sahebrao Katkar	For and on behalf of the Board of Directors
	Sahebrao	N: c=IN, o=Personal, sostalCode=411032, t=MAHARASHTRA, erialNumber=4740b51fec2d8171c 187d12e8a13053d656c1df0736c51 10937dd0fe8e3d777a, cn=Kailash	Kailash Katkar
Place: Pune	Katkar / s	ahebrao Katkar Date: 2021.05.15 17:30:13 +05'30'	Managing Director
Date: May 15, 2021		2021.03.13 17.30.13 403 30	& Chief Executive Officer

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408

STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31, 2021

		xcept per share data)
	As at March 31, 2021 (Audited)	As at March 31, 2020 (Audited)
Assets		
Non-current assets		
(a) Property, plant and equipment	1,404.45	1,484.82
(b) Capital work-in-progress	21.10	34.00
(c) Intangible assets	52.65	99.61
(d) Investments in subsidiaries	122.28	100.64
(e) Financial assets	222.00	252.22
(i) Investments	322.00 3.75	353.32
(ii) Loans and security deposits (iii) Other financial assets	1.62	3.81 3.91
(f) Deferred tax assets (net)	1.02	25.86
(g) Income tax assets (net)	- 121.49	167.92
(b) Other non-current assets	24.64	5.32
(ii) Other non-current assets	24.04	2,279.21
Current assets	2,010130	_,,
(a) Inventories	32.96	62.19
(b) Financial assets		
(i) Investments	3,833.10	2,745.22
(ii) Trade receivables	1,494.62	1,132.26
(iii) Cash and cash equivalents	95.35	35.57
(iv) Bank balances other than (iii) above	678.87	699.53
(v) Loans and security deposits	6.72	7.08
(vi) Interest accrued	7.95	15.30
(c) Other current assets	66.72	23.42
(d) Assets classified as held for sale	16.02	-
	6,232.31	4,720.57
Total assets	8,306.29	6,999.78
Equity and liabilities		
Equity		
(a) Equity share capital	642.07	642.03
(b) Other equity		
(i) Retained earnings	5,816.79	4,747.59
(ii) Securities premium	594.33	593.84
(iii) Amalgamation reserve	26.45	26.45
(iv) General reserve	450.26	450.26
(v) Capital redemption reserve	63.64	63.64
(vi) Other reserves	(35.50)	(41.68)
Total equity	7,558.04	6,482.13
Liabilities		
Non-current liabilities		
(a) Net employee defined benefit liabilities	3.72	4.62
(b) Other non-current liabilities	-	19.63
(c) Deferred tax liabilities (net)	8.19	-
	11.91	24.25
Current liabilities		
(a) Financial liabilities		
(i) Trade payables	10.00	
(a) Total outstanding dues of micro enterprises and small enterprises	13.28	4.73
(b) Total outstanding dues creditors other than micro enterprises and enterprises	483.86	378.87
(ii) Other financial liabilities	13.30	9.04
(b) Other current liabilities	182.43	83.79
(c) Net employee defined benefit liabilities	11.66	3.94
(d) Income tax liabilities (net)	31.81	13.03
Total liabilities	736.34 748.25	493.40 517.65
Total labilities	8,306.29	6,999.78

Quick Heal Technologies Limited

Regd. Office: Marvel Edge, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408 STANDALONE STATEMENT OF CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2021

1	(₹ in million Year en	n, except per share data)	
Particulars	March 31, 2021	March 31, 2020	
	(Audited)	(Audited)	
A. Cash flow from operating activities	((11011110)	
Profit before tax	1,458.37	1,004.40	
Adjustment to reconcile profit before tax to net cash flows:			
Exceptional items	-	23.17	
Net (gain) / loss foreign exchange differences	(2.89)	(0.28)	
Employee share based payments expense	6.21	1.70	
Depreciation and amortization expense	194.78	216.64	
Interest income	(71.27)	(81.28)	
Provision for doubtful debts and advances	(38.62)	63.50	
Bad debts / property, plant and equipment written off	34.71	1.64	
(Profit) / loss on sale of property, plant and equipment	(0.37)	(5.29)	
Dividend income	-	(67.92)	
Net (gain) on sale of investment	(30.12)	(28.36)	
Net (gain) / loss on FVTPL current investment	(90.03)	(66.28)	
Operating profit before working capital changes	1,460.77	1,061.64	
Movements in working capital:			
(Increase)/decrease in trade receivables	(355.56)	52.52	
(Increase)/decrease in inventories	29.23	(20.78)	
(Increase)/decrease in loans	0.42	(0.71)	
(Increase)/decrease in other financial assets	2.29	0.13	
(Increase)/decrease in other assets	(17.79)	14.63	
Increase/(decrease) in net employee defined benefit liabilities	8.50	(17.93)	
Increase/(decrease) in trade payables	90.42	(1.23)	
Increase/(decrease) in other current liabilities	79.01	(47.60)	
Cash generated from operations	1,297.29	1,040.67	
Direct taxes paid (net of refunds)	(291.59)	(332.83)	
Net cash flow from operating activities (A)	1,005.70	707.84	
B. Cash flow from investing activities			
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress and capital advances)	(88.71)	(113.92)	
Proceeds from sale of property, plant and equipment	0.57	10.61	
Investments in subsidiaries	(21.64)	(13.51)	
Investments in non-current investments (other)	31.32	(34.34)	
Purchase of current investments	(6,218.89)	(6,621.26)	
Sale of current investments	5,251.16	7,550.10	
(Increase)/decrease in bank balances other than cash and cash equivalents	20.66	519.91	
Interest received	78.62	96.67	
Dividends received	-	67.92	
Net cash (used in) investing activities (B)	(946.91)	1,462.18	
C. Cash flow from financing activities			
Dividend paid on equity shares	0.49	(384.68)	
Tax on equity dividend paid	-	(79.65)	
Proceeds from issuance of equity shares (including securities premium)	0.50	0.25	
Payout for buyback of shares	-	(1,750.00)	
Net cash flow (used in) financing activities (C)	0.99	(2,214.08)	
Net (decrease) in cash and cash equivalents (A+B+C)	59.78	(44.06)	
Cash and cash equivalents at the beginning of the year	35.57	79.63	
Cash and cash equivalents at the end of the year	95.35	35.57	
Components of cash and cash equivalents			
Cash on hand	0.55	0.63	
Balances with banks			
On current account	62.73	12.30	
On EEFC account	31.36	3.09	
Cheques on hand	0.71	19.55	
Total cash and cash equivalents	95.35	35.57	



Floor 6, Building No. 1 Cerebrum IT Park, Kalyani Nagar Pune 411014, INDIA Tel: +91 20 6763 3400

Independent Auditor's Report on Quarterly Consolidated Financial Results and Year to Date Consolidated Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To the Board of Directors of Quick Heal Technologies Limited

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Quick Heal Technologies Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), its associates and jointly controlled entities quarter and year ended March 31, 2021, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements results of the subsidiaries, the aforesaid Statement:

Sr. No	Name of the Entity	Relationship with the Holding Company	
1.	Quick Heal Technologies America Inc.	Wholly Owned Subsidiary	
2.	Seqrite Technologies DMCC	Wholly Owned Subsidiary	
3.	Quick Heal Technologies Japan KK	Wholly Owned Subsidiary	
4.	Quick Heal Technologies Africa Limited	Wholly Owned Subsidiary	

(i) include the annual financial results of the following entities

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2021.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.



In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent possible.



Other Matters

- 1. The Statement include the audited Financial Results of 4 subsidiaries, whose Financial Results reflect Group's share of total assets of Rs. 95.03 million as at March 31, 2021, Group's share of total revenue of Rs. (2.62) million and Rs. 35.58 million and Group's share of total net profit after tax of Rs 1.26 million and Rs. 5.98 million for the for the quarter ended March 31, 2021 and period from April 01, 2020 to March 31, 2021 respectively, as considered in the Statement, which have been audited by their respective independent auditors. The independent auditors' reports on financial statements/ Financial Results/financial information of these entities have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- 2. The Statement include the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For MSKA & Associates Chartered Accountants ICAI Firm Registration No.105047W

NITIN MANOHAR JUMANI Digitally signed by NITIN MANOHAR JUMANI Date: 2021.05.15 17:28:18 +05'30'

Nitin Manohar Jumani Partner Membership No.: 111700 UDIN: 21111700AAAACK8615

Place: Pune Date: May 15, 2021





Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To the Board of Directors of Quick Heal Technologies Limited

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Quick Heal Technologies Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2021 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Board of Directors' Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement include the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of this matter.

For MSKA & Associates Chartered Accountants ICAI Firm Registration No.105047W



Nitin Manohar Jumani Partner Membership No. 111700 UDIN: 21111700AAAACJ5336

Place: Pune Date: May 15, 2021





This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.





Agenda






Q4FY21 & FY21 EARNINGS HIGHLIGHTS



Q4 & FY21 Earnings Highlights





New enterprise customers with more than 500 users added in FY21:

222	>=500 to <=999	>=1,000 to <=4999	>=5000	Total
Q1	3	0	0	3
Q2	14	5	0	19
Q3	12	5	1	18
Q4	16	12	1	29






COMPANY OVERVIEW

Company at a glance





Purpose

Innovate to "simplify" securing digital experience.

Vision


To be trusted by our customers in securing the digital world and aim to grow as reputable global market leader.

Mission

Empowering the team to solve business problems.

Our journey





Over 25 years of simplifying security

Scripting a new success story In the cybersecurity industry




- India's first listed cybersecurity products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Seqrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts and engineers leverages a combination of AI, cloud and patented technologies to deliver timely and advanced protection
- Solutions to secure across platforms

Shareholder information



Shareholding structure – 31st March 2021



Shareholder Information (as on 31st March 2021)

NSE Ticker	QUICKHEAL	
BSE Ticker	539678	
Market Cap (INR mln)	10,148	
% Free-float	27.17%	
Free-float market cap (INR mln)	2,757	
Total Debt (INR mln)		
Cash & Cash Equivalents (INR mln)	4,809	
Shares Outstanding	6,42,07,868	
3M ADTV (Shares)*	5,96,783	
3M ADTV (INR mln)*	108.7	
Industry	IT Software Products	

*Source: NSE



INDUSTRY OVERVIEW

and the second state of the second state and the second state of the second state of the second state and the second state of the second state of the second state and the second state of the second state of the second state and states in the second state of the second states in the second states in

an Remarting Baffung ab

11 11 12 14 1

TRA NAT

11 3 N

-

stand in such that is the little in such a such as the

THE DOLLARS.

11 13 27 42 11 11 11 11 11 11 11 11 11 11 11


JE TH H


2020 Cyber threat landscape shows that...



1,410 **~** Worm Infection 306 Cryptojacking \$ Attacks 261 Exploit 2458 Infector ГÂЛ × 1.364 8 PUA & Adware 13.733 Malware 137 Ransomware MINUTES

Detection Highlights - 2020






Source: Segrite Threat Report 2021

Low -

...cyber-attacks continue to grow in scale and sophistication...





Adware: 150K


Per Day: 441


Per Hour: 18.4

Per Minute: 0.31

...and rapid digitization has enhanced need for a greater cybersecurity investments


Digital Transactions – INR Crore





Quick Heal

Security Simplified



Source: The Ministry of Electronics and Information Technology, TRAI, Government of India, Statista, Google report – Insights for Brands, KPMG Report – Fintech In India, India Data Diviner – Macquarie



Cyber threat predictions for 2021 and beyond



03 Techniques similar to Operation SideCopy

Quick Heal

Security Simplified

04 CobaltStrike: Powerhouse of Ethical Hackers in the Hands of Cyber Criminals

SEGRITE

Enternrise Outersequrity Colutions by O

Increase in threats on Remote Work Infrastructure Next wave of Crypto-miners **07** Coronavirus themed threats to divert from precautionbased to prevention-based **08** New additions in exploits leveraging weak crypto implementations

09 Deep-fakes to cyber-frauds

Automation in performing phishing attacks

10

Attacks on Red Team tools 12 Increase in attacks related to mobile banking






THE QUICK HEAL ADVANTAGE

Quick Heal is well positioned to leverage its strengths to capture the future opportunities





Strong threat detection and prevention capabilities...





Powers SIGNATURE-LESS and SIGNATURE-BASED detections

Our best and the most innovative malware hunting engine brings together the best of the best!



F

Patented Behavior Detection System







Cloud Based Deep Learning Module



...with State-of-the-Art **Research & Development** leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers


Product **Security Labs Management Team** Detect and analyze Ensures that we build threat vectors across the right products for the globe and provide the right markets at ß advanced protection to the right time customers Incidence **Product Response Team** Development Ensures customers are Team unaffected by critical Designing & building attacks/ outages by cutting edge responding promptly products & solutions **Research & Development** Internet of Things (IOT) **Security Team** Quality Creating solutions to **Assurance Team** ensure all your connected devices are secure

New Launch...



Integrate your cybersecurity to make data-driven solutions from a single dashboard

#GetTheHawkkAdvantage




Product Portfolio – Home, SOHO & Mobile





Robust sales & distribution network in India





Complimentary support from Quick Heal

Zonal and regional sales team to engage and support channel

Landscape across Class B &C towns

Growing presence of T1 distributors across B&C towns. Strong network of T2 resellers - across Class B and Class

QUICK HEAL Global Presence





23



Committed to deliver exceptional **CUSTOMER EXPERIENCE**

Multi-lingual end user support in English, Hindi and several other major regional Indian languages

2 Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms

Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



Experienced Board of Directors





Dr. Kailash Katkar MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Air Marshal (Retd) Bhushan Nilkanth Gokhale Independent Director

Served on the board of defense PSUs and adviser to government institutions. Appointed as Independent Security Advisor in Ministry of Home Affairs.



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi Independent Director

Certified bank forensic accounting professional and anti – money laundering expert

...along with strong Management...



Dr. Kailash Katkar MD & CEO

Co-founder of the Company

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.



Dr. Sanjay Katkar Joint MD & CTO

Co-founder of the Company

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.



...and seasoned Leadership team





Mr. Nitin Kulkarni CFO

25+ years of experience in managing different aspects of finance in IT and Manufacturing Industry.

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems.

A member of the Institute of Chartered Accountants of India.



Ms. Reetu Raina CHRO

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Sanjay Agrawal CPO

Responsible for driving the overall product vision and strategy in line with market expectations.

Sanjay is an entrepreneurial engineering and product leader with two decades of experience and proven success in building cybersecurity products for the global markets.

A computer engineering graduate from University of Illinois, Sanjay holds a Ph.D. and M.S. from Stanford University in Electrical Engineering and Computer Science (EECS).

...and seasoned Leadership team



Mr. Bibhuti Kar Head, R&D

Responsible for driving company's development efforts leading a team of talented engineering professionals and security researchers.

Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry.

An alumnus of IIT Kharagpur with a master's in ECE, he has worked on missile communication systems with DRDO.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

Over two decades of diverse sales experience including leadership roles in cybersecurity companies.





Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

Over two decades of experience in FMCG, Beverages, Telecom and IT Industries.

Strong brand recognition...





...backed by Certifications, Patents and...

International & ISO Certifications





Cybersecurity Product Pioneer in India



Patented Technologies

USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

USPTO 10,311,234 Anti-Ransomware technology

USPTO 8,973,136

System and method for protecting computer systems from malware attacks

USPTO 8,914,908

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software

Securing the future through our community initiatives





Lives directly impacted since 2016



Cybersecurity

- Cybersecurity Awareness
- Cyber Shiksha for Suraksha
- Street Plays





Lives impacted since 2020



Covid-19 Relief Initiatives

- Free immunity boosters medicines to frontline workers
- Organised health camps and assisted in the smooth functioning of Covid-19 centres
- Donated medical vans to NGOs to heal tribal population
- Distribution of food grains to the needy during lockdown
- Distribution of PPE kits to NGOs
- Donated to PM Cares Fund



45,000+ Lives directly impacted since 2016



Education

• Life Skills Education for underprivileged children



Quick Heal Academy to drive the next generation of cyber security experts





Popular Courses

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- ✓ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

Offerings





Academy Partners

Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University

Quantum University

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

Manav Rachna University

MoU with Manav Rachna University (MRU) for a joint B. Tech in Cyber Security & Threat Intelligence, programme

Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra

Chitkara University

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program

Parul University

MoU with Parul University, Vadodara for Joint B. Tech Programme (4 Years)

Disclaimer: Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose

NEW

NEW




Quick Heal Security Simplified

Q4 & FY21 EARNINGS


Q4FY21 – Consolidated Performance Highlights






FY21 – Consolidated Performance Highlights





Q4FY21 Segment performance






Based on net revenues before adjusting for sales incentives


FY21 Segment performance



Retail







Based on net revenues before adjusting for sales incentives

Q4FY21 – Profitability statement



Total Revenue 634.31 1061.05 6 Direct Cost 29.78 45.57 6 Gross Profit 604.53 1,015.48 6 Gross Margin 95.31% 95.71% 6 Operating Cost 128.47 172.81 6 Sales and Marketing (S&M) 234.67 166.52 6 General Administration (G&A) 161.13 135.41 7 Total Expenditure 524.27 474.74 7	changeQ4FY2067.28%642.5434.14	1,052.94	% change
Direct Cost 29.78 45.57 Gross Profit 604.53 1,015.48 6 Gross Margin 95.31% 95.71% 6 Operating Cost 128.47 172.81 6 Research and Development (R&D) 128.47 166.52 6 Sales and Marketing (S&M) 234.67 166.52 6 General Administration (G&A) 161.13 135.41 6		-	
Gross Profit 604.53 1,015.48 6 Gross Margin 95.31% 95.71% 6 Operating Cost 128.47 172.81 6 Research and Development (R&D) 128.47 166.52 6 Sales and Marketing (S&M) 234.67 166.52 6 General Administration (G&A) 161.13 135.41 6 Total Expenditure 524.27 474.74 6	34.14		63.87%
Gross Margin 95.31% 95.71% Operating Cost Research and Development (R&D) 128.47 172.81 Sales and Marketing (S&M) 234.67 166.52 General Administration (G&A) 161.13 135.41 Total Expenditure 524.27 474.74		45.44	
Operating Cost 128.47 172.81 Research and Development (R&D) 234.67 166.52 Sales and Marketing (S&M) 161.13 135.41 General Administration (G&A) 524.27 474.74	67.98% 608.40	1,007.50	65.60%
Research and Development (R&D) 128.47 172.81 Sales and Marketing (S&M) 234.67 166.52 General Administration (G&A) 161.13 135.41 Total Expenditure 524.27 474.74	40bps 94.69%	95.68%	100bps
Sales and Marketing (S&M) 234.67 166.52 General Administration (G&A) 161.13 135.41 Total Expenditure 524.27 474.74			
General Administration (G&A) 161.13 135.41 Total Expenditure 524.27 474.74	128.47	172.81	
Total Expenditure524.27474.74	238.58	170.36	
•	165.50	126.55	
	9.45% 532.55	469.72	11.80%
EBITDA 80.26 540.74 57	73.74% 75.85	537.78	609.00%
EBITDA Margin 12.65% 50.96% 38	831bps 11.80%	51.07%	3927bps
Depreciation 55.88 49.98	55.93	50.00	
EBIT 24.38 490.76 192	12.96% 19.92	487.78	2348.69%
EBIT Margin 3.84% 46.25% 42	241bps 3.10%	46.33%	4323bps
Other Income 81.12 57.24	82.42	57.34	
Profit Before Tax (Before exceptional item)105.50548.0042	19.43% 102.34	545.12	432.66%
Exceptional Item 23.17 -	-	-	
Profit Before Tax 82.33 548.00 56	65.61% 102.34	545.12	432.66%
Tax 22.09 147.62	22.41	147.86	
Profit After Tax (PAT) 60.24 400.38 56	64.64% 79.93	397.26	397.01%
PAT Margin 9.50% 37.73% 28	824bps 12.44%	37.73%	2529bps

FY21 – Profitability statement

	Standalone			Consolidated		
PARTICULARS (₹ mln)	FY20	FY21	% change	FY20	FY21	% change
Total Revenue	2,834.04	3,335.28	17.69%	2,861.38	3,330.44	16.39%
Direct Cost	111.75	134.24		124.13	136.97	
Gross Profit	2,722.29	3,201.04	17.59%	2,737.25	3,193.47	16.67%
Gross Margin	96.06%	95.98%	-8bps	95.66%	95.89%	23bps
Operating Cost						
Research and Development (R&D)	532.90	634.44		532.90	634.44	
Sales and Marketing (S&M)	714.69	649.25		731.18	665.07	
General Administration (G&A)	543.90	503.57		559.26	479.34	
Total Expenditure	1,791.49	1,787.26	0.24%	1,823.34	1,778.85	2.44%
EBITDA	930.80	1,413.78	51.89%	913.91	1,414.62	54.79%
EBITDA Margin	32.84%	42.39%	955bps	31.94%	42.48%	1054bps
Depreciation	216.64	194.78		216.77	194.87	
EBIT	714.16	1,219.00	70.69%	697.14	1,219.75	74.97%
EBIT Margin	25.20%	36.55%	1135bps	24.36%	36.62%	1226bps
Other Income	313.41	239.37		315.96	241.61	
Profit Before Tax (Before exceptional item)	1,027.57	1,458.37	41.92%	1,013.10	1,461.36	44.25%
Exceptional Item	23.17	-		-	-	
Profit Before Tax	1,004.40	1,458.37	45.20%	1,013.10	1,461.36	44.25%
Тах	268.01	390.43		269.00	391.57	
Profit After Tax (PAT)	736.39	1,067.94	45.02%	744.10	1,069.79	43.77%
PAT Margin	25.98%	32.02%	604bps	26.00%	32.12%	612bps

Quick Heal

Security Simplified

SEG

Enterprise Cybersecurity Solutions

ITE



In %	Stand	alone	Consolidated		
	Q4FY20	Q4FY21	Q4FY20	Q4FY21	
Expenses					
Direct Cost / Revenue	4.69%	4.29%	5.31%	4.32%	
R&D / Revenue	20.25%	16.29%	19.99%	16.41%	
S&M / Revenue	37.00%	15.69%	37.13%	16.18%	
G&A / Revenue	25.40%	12.76%	25.76%	12.02%	
Total Cost / Revenue	82.65%	44.74%	82.88%	44.61%	
Margin					
Gross Margin	95.31%	95.71%	94.69%	95.68%	
EBITDA	12.65%	50.96%	11.80%	51.07%	
EBIT	3.84%	46.25%	3.10%	46.33%	
РВТ	12.98%	51.65%	15.93%	51.77%	
PAT	9.50%	37.73%	12.44%	37.73%	



In %	Stand	alone	Consolidated		
	FY20	FY21	FY20	FY21	
Expenses					
Direct Cost / Revenue	3.94%	4.02%	4.34%	4.11%	
R&D / Revenue	18.80%	19.02%	18.62%	19.05%	
S&M / Revenue	25.22%	19.47%	25.55%	19.97%	
G&A / Revenue	19.19%	15.10%	19.55%	14.39%	
Total Cost / Revenue	63.21%	53.59%	63.72%	53.41%	
Margin					
Gross Margin	96.06%	95.98%	95.66%	95.89%	
EBITDA	32.84%	42.39%	31.94%	42.48%	
EBIT	25.20%	36.55%	24.36%	36.62%	
PBT	35.44%	43.73%	35.41%	43.88%	
PAT	25.98%	32.02%	26.00%	32.12%	

Consolidated Balance Sheet



EQUITY AND LIABILITIES (₹ mln)	Mar 31, 2020	Mar 31, 2021
Share Holder's Funds:		
Equity Share Capital	642.03	642.07
Share application money pending allotment	-	-
Reserves and Surplus	5,798.65	6,872.79
Total Shareholder Funds	6,440.68	7,514.86
Non-Current Liabilities		
Net employee defined benefit liabilities	4.62	3.72
Other Non Current Liabilities	19.63	-
Deferred tax liability (net)	-	8.19
Total Non-Current Liabilities	24.25	11.91
Current Liabilities:		
Trade and Other Payables	387.27	499.77
Other Financial Liabilities	9.04	13.30
Other Current Liabilities	86.68	183.07
Net employee defined benefit liabilities	3.94	11.66
Current tax liabilities (Net)	13.80	32.30
Total Current Liabilities	500.73	740.10
Total Equity & Liabilities	6,965.66	8,266.87

ASSETS (₹ mln)	Mar 31, 2020	Mar 31, 2021
Non-Current Assets:		
Property, plant and equipment	1,485.09	1,404.67
Capital work-in-progress	34.00	21.10
Intangible assets	99.81	52.81
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	353.32	322.00
Loan and Security Deposits	3.81	3.75
Bank Balances	3.91	1.62
Deferred tax assets (net)	25.86	-
Other non current assets	173.24	146.13
Total Non-Current Assets	2,179.04	1,952.08
Current assets:		
Inventories	62.40	33.35
Investment in Mutual Fund	2,745.22	3,833.10
Trade and other receivables	1,131.62	1,506.30
Bank Balances & Cash and Cash Equivalents	101.73	165.73
Investment in Fixed Deposit	698.52	677.37
Loan and security deposits	7.74	6.79
Interest accrued on FDR and Tax-Free Bonds	15.26	7.95
Other Current assets	24.13	68.18
Assets classified as held for sale	-	16.02
Total Current Assets	4,786.62	6,314.79
Total Assets	6,965.66	8,266.87

NOTE: Certain figures have been re-grouped wherever necessary

Standalone Balance Sheet



EQUITY AND LIABILITIES (₹ mln)	Mar 31, 2020	Mar 31, 2021
Share Holder's Funds:		
Equity Share Capital	642.03	642.07
Share application money pending allotment	-	-
Reserves and Surplus	5,840.10	6,915.97
Total Shareholder Funds	6,482.13	7,558.04
Non-Current Liabilities		
Net employee defined benefit liabilities	4.62	3.72
Other Non Current Liabilities	19.63	-
Deferred tax liability (net)	-	8.19
Total Non-Current Liabilities	24.25	11.91
Current Liabilities:		
Trade and Other Payables	383.60	497.14
Other Financial Liabilities	9.04	13.30
Other Current Liabilities	83.79	182.13
Net employee defined benefit liabilities	3.94	11.66
Current tax liabilities (Net)	13.03	31.81
Total Current Liabilities	493.40	736.34
Total Equity & Liabilities	6,999.78	8,306.29

ASSETS (₹ mln)	Mar 31, 2020	Mar 31, 2021
Non-Current Assets:		
Property, plant and equipment	1,484.82	1,404.45
Capital work-in-progress	34.00	21.10
Intangible assets	99.61	52.65
Non-current financial assets		
Investments in MF, Tax-Free Bonds, Subsidiaries & others	453.96	444.28
Loan and Security Deposits	3.81	3.75
Bank Balances	3.91	1.62
Deferred tax assets (net)	25.86	-
Other non current assets	173.24	146.13
Total Non-Current Assets	2,279.21	2,073.98
Current assets:		
Inventories	62.19	32.96
Investment in Mutual Fund	2,745.22	3,833.10
Trade and other receivables	1,132.26	1,494.62
Bank Balances & Cash and Cash Equivalents	36.58	96.85
Investment in Fixed Deposit	698.52	677.37
Loan and security deposits	7.08	6.72
Interest accrued on FDR and Tax-Free Bonds	15.30	7.95
Other Current assets	23.42	66.72
Assets classified as held for sale	-	16.02
Total Current Assets	4,720.57	6,232.31
Total Assets	6,999.78	8,306.29

NOTE: Certain figures have been re-grouped wherever necessary


Working capital analysis





At the end of March, 2020*



At the end of March, 2021*







Note*

Receivable Days = [(Debtors/ Sales) X (365 days)] Inventory Days = [(Inventory/Sales) X (365 days)] Payable Days = [(Creditor/Sales) X (365 days)]


Note**

Receivable Days = [(Debtors/ Sales) X (275 days)] Inventory Days = [(Inventory/Sales) X (275 days)] Payable Days = [(Creditor/Sales) X (275 days)]

Calculation is based on net revenues before adjusting for sales incentives

Return ratio analysis





Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
 Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

RoCE = EBIT / Avg. Capital Employed (Equity + Debt) **Cash Adj. RoCE** = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

ROE = PAT / Avg. Equity





Thank You

Chief Financial Officer

Mr. Nitin Kulkarni Nitin.Kulkarni@quickheal.co.in +91-20-66813232

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

CIN No: L72200MH1995PLC091408 www.quickheal.co.in

Annexure

Products Sold in following countries

- Australia
- Bangladesh
- Benin
- Cambodia
- Canada
- Chile
- Colombia
- Congo
- Ecuador
- El Salvador
- France
- Gambia

- - Guinea
 - Honduras
- Italy
- Japan
- Kuwait
- Macao

- Germany

- Jordan
- Kenva
- Malaysia
 - Mauritius

- Mexico Morocco
- Hong Kong
 - - Saudi Arabia
 - Singapore

Nigeria

 Solomon Islands South Africa

Netherlands

New Zealand

- South Korea
- Sri Lanka
- Panama

- Paraguay
- Peru
- Philippines
- Qatar
- Rwanda
- Thailand
- Turkey
- Uganda
- UAE
- USA
 - Venezuela

Sales & Support offices across India

- Chandigarh
- New Delhi
- Jaipur
- Lucknow
- Patna
- Guwahati
- Ahmedabad
- Indore
- Surat
- Nashik
- Nagpur

- Mumbai
- Pune
- Aurangabad

Quick Heal

Security Simplified

- Kolhapur
- Raipur
- Kolkata
- Bhubaneshwar

47

- Hyderabad
- Bangalore
- Chennai
- Kochi





Press Release

FOR IMMEDIATE RELEASE

Quick Heal Technologies Limited reports strong growth in FY21 despite disruptions caused by the pandemic

- Revenue at ₹3,330 mln up 16.4% YoY
- EBITDA at ₹1,415 mIn up 54.8% YoY with EBITDA margin of 42.5%
- PAT at ₹1,070 mln up 43.8% YoY
- Board announces dividend of ₹4 per equity share with a face value of ₹10 per share subject to shareholder's approval in the ensuing AGM

Pune, May 15, 2021: Quick Heal Technologies Limited ("Quick Heal"), one of the leading providers of cybersecurity and data protection solutions to consumers, businesses and Government, reported its audited results for the quarter and full year ended 31st March 2021.

Particulars (₹ million)	Q4FY21	Q4FY20	YoY Change	FY21	FY20	YoY Change
Revenue	1,053	643	63.9%	3,330	2,861	16.4%
EBITDA	538	76	609.0%	1,415	914	54.8%
EBITDA Margin	51.1%	11.8%	3927bps	42.5%	31.9%	1054bps
PAT	397	80	397.1%	1,070	744	43.8%
PAT Margin	37.7%	12.4%	2529bps	32.1%	26.0%	612bps

Consolidated Financial Highlights:

Dr. Kailash Katkar, Managing Director & Chief Executive Officer, Quick Heal Technologies Limited, said; "We are delighted to conclude FY21 on a high note. We would like to thank our employees and partners for their relentless efforts and dedication as we continued to deliver the best-in-class security solutions to our customers. Our ongoing investments in building newer capabilities and strengthening of the leadership team, position us well to launch next-generation solutions and build a solid foundation for the enterprise business. However, the new wave of pandemic has once again presented a challenging operating environment with lockdown imposed in multiple states. As vaccination picks up momentum, we are hopeful that the situation will improve in due course of time."

Mr. Nitin Kulkarni, Chief Financial Officer, Quick Heal Technologies Limited, added "We have delivered strong financial performance for the quarter and closed the year on a positive note. During the quarter, along with strong top line growth, we managed to significantly improve EBITDA margin due to our constant focus on improving the operational efficiencies. In line with our philosophy of constantly rewarding shareholders, during the last quarter we announced buyback of equity shares which also fits with our robust capital allocation policy and should be EPS accretive. Our balance sheet remains strong with zero debt and cash and cash equivalents of around ₹4,809 mln."



Segmental Performance for full year ended 31st March 2021

- ✓ Retail segment revenue at ₹2,994 million compared to ₹2,422 in FY20. Retail segment contributed
 81.8% to total revenue in FY21
- ✓ Enterprise and Government segment revenue at ₹665 million compared to ₹609 mln in FY20.
 Enterprise segment contributed 18.2% to total revenue in FY21

Key updates:

- Quick Heal Technologies has announced buyback of 63,26,530 equity shares of the company constituting 9.85% of the paid up equity share capital of the Company, for an aggregate amount not exceeding ₹ 1,550 million at ₹245 per equity share.
- The Board of Directors have declared a final dividend of ₹4 per equity share with a face value of ₹10 per share for FY2020-2021 which is subject to shareholders' approval in ensuing annual general meeting.

About Quick Heal Technologies Limited

Quick Heal Technologies Limited is one of the leading providers of IT Security and Data Protection Solutions with a strong footprint in India and an evolving global presence. Incorporated in the year 1995, with a registered office in Pune, it is an all-round player in cybersecurity with presence in B2B, B2G and B2C segments and multiple product categories – endpoints, network, data and mobility.

It helps in simplifying security by delivering best-in-class protection against advanced cyber-threats to millions of its customers and enterprises. Quick Heal's portfolio includes solutions under the widely recognized brand names 'Quick Heal' and 'Seqrite' across various operating systems and devices.

For more information about the Company, please visit our website www.quickheal.co.in

Safe Harbor Statement

This document may contain forward-looking statements about Quick Heal Technologies Limited, which are based on the beliefs, opinions, and expectations of the company's management as the date of this press release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements. **For further details please contact**

Company

Quick Heal Technologies Limited

CIN No: L72200MH1995PLC091408

Mr. Akash Gosavi

Email Id: akash.gosavi@quickheal.co.in_Tel. No.: +91 20 6681 3287